Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
Della Starza I, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, Menale L, Soscia R, Apicella V, Ilari C, Vitale A, Testi AM, Inghirami G, Chiaretti S, Foà R, Guarini A. Della Starza I, et al. Among authors: de novi la. Leuk Lymphoma. 2019 Nov;60(11):2838-2840. doi: 10.1080/10428194.2019.1607325. Epub 2019 May 3. Leuk Lymphoma. 2019. PMID: 31050551 No abstract available.
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Della Starza I, De Novi LA, Cavalli M, Novelli N, Soscia R, Genuardi E, Mantoan B, Drandi D, Ferrante M, Monitillo L, Barbero D, Ciabatti E, Grassi S, Bomben R, Degan M, Gattei V, Galimberti S, Di Rocco A, Martelli M, Cortelazzo S, Guarini A, Foà R, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Della Starza I, et al. Among authors: de novi la. Hematol Oncol. 2020 Dec;38(5):698-704. doi: 10.1002/hon.2792. Epub 2020 Aug 28. Hematol Oncol. 2020. PMID: 32816326
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.
Ansuinelli M, Della Starza I, Lauretti A, Elia L, Siravo V, Messina M, De Novi LA, Taherinasab A, Canichella M, Guarini A, Foà R, Chiaretti S. Ansuinelli M, et al. Among authors: de novi la. Hematol Oncol. 2021 Dec;39(5):680-686. doi: 10.1002/hon.2913. Epub 2021 Aug 16. Hematol Oncol. 2021. PMID: 34402088 Free PMC article.
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Della Starza I, Chiaretti S, De Propris MS, Elia L, Cavalli M, De Novi LA, Soscia R, Messina M, Vitale A, Guarini A, Foà R. Della Starza I, et al. Among authors: de propris ms, de novi la. Front Oncol. 2019 Aug 7;9:726. doi: 10.3389/fonc.2019.00726. eCollection 2019. Front Oncol. 2019. PMID: 31448230 Free PMC article. Review.
Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
Pulsoni A, Della Starza I, Cappelli LV, Tosti ME, Annechini G, Cavalli M, De Novi LA, D'Elia GM, Grapulin L, Guarini A, Del Giudice I, Foà R. Pulsoni A, et al. Among authors: de novi la. Br J Haematol. 2020 Jan;188(2):249-258. doi: 10.1111/bjh.16125. Epub 2019 Aug 5. Br J Haematol. 2020. PMID: 31385309 Free article.
Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
Soscia R, Della Starza I, De Novi LA, Ilari C, Ansuinelli M, Cavalli M, Bellomarino V, Cafforio L, Di Trani M, Cazzaniga G, Fazio G, Santoro A, Salemi D, Spinelli O, Tosi M, Terragna C, Robustelli V, Bellissimo T, Colafigli G, Breccia M, Chiaretti S, Di Rocco A, Martelli M, Guarini A, Del Giudice I, Foà R. Soscia R, et al. Among authors: de novi la. Hematol Oncol. 2023 Feb;41(1):50-60. doi: 10.1002/hon.3087. Epub 2022 Oct 19. Hematol Oncol. 2023. PMID: 36251440
22 results